Radiotherapy with or without immunotherapy in metastatic melanoma: efficacy and tolerability

References

• Socialstyrelsen. Statistics on Cancer Incidence 2020 Socialstyrelsen: socialstyrelsen; 2021 [cited 2021 2021-12-15]. Available from: www.socialstyrelsen.se/statistik-och-data/statistik/statistikamnen/cancer/.
   Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019; Oct 17381(16):1535–1546. doi: 10.1056/NEJMoa1910836.
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582–588. doi: 10.1093/annonc/mdz011.
   PubMed Web of Science ®Google Scholar
• Corso CD, Ali AN, Diaz R. Radiation-induced tumor neoantigens: imaging and therapeutic implications. Am J Cancer Res. 2011;1(3):390–412.
   PubMed Web of Science ®Google Scholar
• Voronova V, Vislobokova A, Mutig K, et al. Combination of immune checkpoint inhibitors with radiation therapy in cancer: a hammer breaking the wall of resistance. Front Oncol. 2022;12:1035884. doi: 10.3389/fonc.2022.1035884.
   PubMedGoogle Scholar
• Wang Y, Deng W, Li N, et al. Combining immunotherapy and radiotherapy for cancer treatment: current challenges and future directions. Front Pharmacol. 2018;9:185. doi: 10.3389/fphar.2018.00185.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Aryankalayil MJ, Coleman CN, et al. Emerging evidence for adapting radiotherapy to immunotherapy. Nat Rev Clin Oncol. 2023; 20(8):543–557. doi: 10.1038/s41571-023-00782-x.
   PubMed Web of Science ®Google Scholar
• Janopaul-Naylor JR, Shen Y, Qian DC, et al. The abscopal effect: a review of pre-clinical and clinical advances. Int J Mol Sci. 2021;22(20):11061. doi: 10.3390/ijms222011061.
   PubMed Web of Science ®Google Scholar
• Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol. 1953; 26(305):234–241. doi: 10.1259/0007-1285-26-305-234.
   PubMed Web of Science ®Google Scholar
• Abuodeh Y, Venkat P, Kim S. Systematic review of case reports on the abscopal effect. Curr Probl Cancer. 2016;40(1):25–37. doi: 10.1016/j.currproblcancer.2015.10.001.
   PubMed Web of Science ®Google Scholar
• Khalifa J, Mazieres J, Gomez-Roca C, et al. Radiotherapy in the era of immunotherapy with a focus on non-small-cell lung cancer: time to revisit ancient dogmas? Front Oncol. 2021;11:662236. doi: 10.3389/fonc.2021.662236.
   PubMed Web of Science ®Google Scholar
• Yin G, Guo W, Huang Z, et al. Efficacy of radiotherapy combined with immune checkpoint inhibitors in patients with melanoma: a systemic review and meta-analysis. Melanoma Res. 2022; 32(2):71–78. doi: 10.1097/CMR.0000000000000800.
   PubMed Web of Science ®Google Scholar
• Nabrinsky E, Macklis J, Bitran J. A review of the abscopal effect in the era of immunotherapy. Cureus. 2022; 14(9):e29620. doi: 10.7759/cureus.29620.
   PubMed Web of Science ®Google Scholar
• Keung EZ, Gershenwald JE. The eighth edition American joint committee on cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther. 2018; 18(8):775–784. doi: 10.1080/14737140.2018.1489246.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45(2):228–247. doi: 10.1016/j.ejca.2008.10.026.
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015; 372(4):320–330. doi: 10.1056/NEJMoa1412082.
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015; 372(26):2521–2532. doi: 10.1056/NEJMoa1503093.
   PubMed Web of Science ®Google Scholar
• Trommer M, Yeo SY, Persigehl T, et al. Abscopal effects in radio-immunotherapy-response analysis of metastatic cancer patients with progressive disease under anti-PD-1 immune checkpoint inhibition. Front Pharmacol. 2019;10:511. doi: 10.3389/fphar.2019.00511.
   PubMed Web of Science ®Google Scholar
• Chandra RA, Wilhite TJ, Balboni TA, et al. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology. 2015; 4(11):e1046028. doi: 10.1080/2162402X.2015.1046028.
   PubMed Web of Science ®Google Scholar
• Saiag P, Molinier R, Roger A, et al. Efficacy of large use of combined hypofractionated radiotherapy in a cohort of anti-PD-1 monotherapy-treated melanoma patients. Cancers. 2022; 14(17):4069. doi: 10.3390/cancers14174069.
   PubMed Web of Science ®Google Scholar
• Czarnecka AM, Sobczuk P, Rogala P, et al. Efficacy of immunotherapy beyond RECIST progression in advanced melanoma: a real-world evidence. Cancer Immunol Immunother. 2022;71(8):1949–1958. doi: 10.1007/s00262-021-03132-x.
   PubMed Web of Science ®Google Scholar
• Chicas-Sett R, Zafra J, Rodriguez-Abreu D, et al. Combination of SABR with anti-PD-1 in oligoprogressive non-small cell lung cancer and melanoma: results of a prospective multicenter observational study. Int J Radiat Oncol Biol Phys. 2022;114(4):655–665. doi: 10.1016/j.ijrobp.2022.05.013.
   PubMed Web of Science ®Google Scholar
• Topp BG, Channavazzala M, Mayawala K, et al. Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression. Cancer Cell. 2023; 41(9):1680–1688 e2. doi: 10.1016/j.ccell.2023.08.004.
   PubMed Web of Science ®Google Scholar
• Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A, et al. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. Int J Radiat Oncol Biol Phys. 1999;44(3):607–618. doi: 10.1016/s0360-3016(99)00066-8.
   PubMed Web of Science ®Google Scholar
• Olivier KR, Schild SE, Morris CG, et al. A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. Cancer. 2007; 110(8):1791–1795. doi: 10.1002/cncr.22988.
   PubMed Web of Science ®Google Scholar
• Mireștean CC, Iancu RI, Iancu DT. Immunotherapy and radiotherapy as an antitumoral long-range weapon-a partnership with unsolved challenges: dose, fractionation, volumes, therapeutic sequence. Curr Oncol. 2022; 29(10):7388–7395. doi: 10.3390/curroncol29100580.
   PubMed Web of Science ®Google Scholar
• Poleszczuk J, Enderling H. The optimal radiation dose to induce robust systemic anti-tumor immunity. Int J Mol Sci. 2018;19(11):3377. doi: 10.3390/ijms19113377.
   PubMed Web of Science ®Google Scholar
• Lugade AA, Moran JP, Gerber SA, et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005; 174(12):7516–7523. doi: 10.4049/jimmunol.174.12.7516.
   PubMed Web of Science ®Google Scholar
• Camphausen K, Moses MA, Menard C, et al. Radiation abscopal antitumor effect is mediated through p53. Cancer Res. 2003;63(8):1990–1993.
   PubMed Web of Science ®Google Scholar
• Wang SJ, Jhawar SR, Rivera-Nunez Z, et al. The association of radiation dose-fractionation and immunotherapy use with overall survival in metastatic melanoma patients. Cureus. 2020; 12(6):e8767. doi: 10.7759/cureus.8767.
   PubMed Web of Science ®Google Scholar
• Tsui JM, Mihalcioiu C, Cury FL. Abscopal effect in a stage IV melanoma patient who progressed on pembrolizumab. Cureus. 2018; 10(2):e2238. doi: 10.7759/cureus.2238.
   PubMed Web of Science ®Google Scholar
• Maity A, Mick R, Huang AC, et al. A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. Br J Cancer. 2018; 119(10):1200–1207. doi: 10.1038/s41416-018-0281-9.
   PubMed Web of Science ®Google Scholar
• Grimaldi AM, Simeone E, Giannarelli D, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology. 2014;3(5):e28780. doi: 10.4161/onci.28780.
   PubMed Web of Science ®Google Scholar
• Thompson JF, Williams GJ, Hong AM. Radiation therapy for melanoma brain metastases: a systematic review. Radiol Oncol. 2022; 56(3):267–284. doi: 10.2478/raon-2022-0032.
   PubMed Web of Science ®Google Scholar
• Liniker E, Menzies AM, Kong BY, et al. Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. Oncoimmunology. 2016;5(9):e1214788. doi: 10.1080/2162402X.2016.1214788.
   PubMed Web of Science ®Google Scholar
• Nomura M, Otsuka A, Yoshimura M, et al. Efficacy and safety of concurrent immunoradiotherapy in patients with metastatic melanoma after progression on nivolumab. Cancer Chemother Pharmacol. 2018;81(5):823–827. doi: 10.1007/s00280-018-3557-0.
   PubMed Web of Science ®Google Scholar
• Backlund E, Yang M, Grozman V, et al. Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial. Acta Oncol. 2022; 61(7):869–873. doi: 10.1080/0284186X.2022.2079959.
   PubMed Web of Science ®Google Scholar